Comparison Of The Efficacy Of SOX Regimen And XELOX Regimen In Postoperative Chemotherapy For Gastric Cancer

Objective:sox(oxaliplatin+s-1)and xelox(oxaliplatin+capecitabine)are both first-line chemotherapy regimen for gastric cancer and have been widely used in clinical practice in recent years.Many studies have shown the curative efficacy of the sox and xelox postoperative chemotherapy treatment,but the sox chemotherapy is more likely to occur with oral mucositis concurrently,xelox is easily complicated with extremities syndrome and peripheral nerve symptoms.Therefore,this study reviews using two kinds of chemotherapy for gastric cancer postoperative patients in the past three years to provide certain reference for the future postoperative chemotherapy after analyze D2lymph node dissection plus radical gastric cancer postoperative chemotherapy curative effects and adverse reactions.Methods:clinical data:36 patients with stage IIa-IIIc D2 radical gastritis were selected within 3 years from September 2016 to September 2019 and were divided into two groups according to the chemotherapy regimen that selected,namely the sox regimen group and the xelox regimen group.There are 18 persons in each group.Sox group:oxaliplatin(according to body surface area):130mg/m~2 D1 intravenous infusion for over 2 hoursviconda(tiggio capsule):according to the instruction,the body surface area was compared,<1.25m~2 40mg per time;1.5 m~2>x>1.25 m~2 50 mg per time;>1.5m~2 60mg per time was taken orally in the morning and evening,D1-D14,and repeated every 3 weeks Xelox regimen group:oxaliplatin(according to body surface area)130mg/m~2 D1intravenous infusion for over 2 hoursxeloda(capecitabine tablets):according to the instruction,body surface area was compared,1000mg/m~2 oral,D1-D14,repeated every 3 weeks.In addition,30 minutes before the first day of chemotherapy,amifostine was given by intravenous drip to enhance the efficacy,and the protective drugs of gastric mucosa,liver protection and antiemetic were given symptomatic treatment during D1-D3.Evaluation indexes:1,2,3 years OS(survival)and RFS(recurrence free survival).Adverse reactions were rated in accordance with CTCAE5.0.Statistical software was used for analysis.X~2 test,Kaplan-meier survival curve and log-rank were used to test and analyze indicators.Results:until 2019-9-30,the RFS of 1,2 and 3 years in the sox group(18 cases)were:94.4%,77.7%and 66.6%.OS in year 1,2 and 3 were:100%,88.9%and 66.6%.The RFS of 1,2 and 3 years in the xelox group(18 cases)were:83.3%,66.6%and 50%.The OS of year 1,2 and 3 years were:100%,88.9%and 61.1%.The median OS of the Sox group was 32.556�1.284 months[95%CI(29.837-35.275)];The median OS of Xelox group was 32.400�1.336 months[95%CI(29.986-34.814)].The median RFS of the SOX group was 29.889�2.052months[95%CI(25.868-33.910)].The median RFS of the Xelox group was 26.667�2.493 months[95%CI(21.780-31.553)].There was no significant difference in OS and RFS between the two groups at 1,2 and 3 years,with no statistical significance.In terms of adverse reactions,hematology and digestive system related adverse reactions were mainly grade I-II in the two groups,with no significant difference.However,the peripheral nerve symptoms of xelox group were more obvious than that of sox group(p=0.035).Conclusion:the efficacy of sox and xelox for postoperative chemotherapy of locally advanced gastric cancer is similar,and the toxic and side effects of the above two chemotherapy schemes are mainly grade I-II,and the peripheral nerve symptoms of xelox regimen are more significant than that of sox.